You are here > Biopharmaceutical
Glossaries & Taxonomies Homepage >
Therapeutic indications > Cancer overview
Cancer & Immuno-Oncology overview glossary & taxonomy
Evolving Terminology for Emerging Technologies
Comments? Questions?
Revisions? Mary Chitty MSLS
mchitty@healthtech.com
Last revised
January 09, 2020
SCOPE
NOTE Cancer
and
oncology
include immuno-oncology, liquid biopsies, CAR T Cell therapies,
circulating tumor cells, neoantigen targeted therapies, NK Natural Killer
Cells based cancer immunotherapies, cancer vaccines, oncolytic virus
immunotherapies, tumor microenvironment
Related glossaries &
taxonomies
Cancer
& Immuno-oncology
Molecular
Diagnostics
Molecular Medicine
Adoptive T Cell Therapy
August 11-12., 2020
Boston, MA
Efforts
to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety
profiles, and efficacy are leading to the second generation of improved
adoptive cell therapies. With multiple engineered receptors already making
preclinical impact, many biotech and pharma companies are preparing for
the next wave of clinical trials. The end goal is still the same: improved
patient outcomes. However, there remain technical considerations and
translational challenges relating to cell therapy development,
manufacturing practicability, clinical trial approaches, cell quality and
persistence, and patient management
https://www.immuno-oncologysummit.com/T-Cell/
Adoptive T Cell Therapy :
Development
August 10-14 , 2020
Boston, MA
https://www.immuno-oncologysummit.com/Adoptive-T-Cell-Therapy-Development/ | In
2017, two CAR T cell therapies were approved by the Food and Drug
Administration (FDA). With multiple engineered receptors making
preclinical impact, many biotech and pharma companies are already entering
other clinical trials in a race to get to market. Has this promising field
finally reached a tipping point? Technical considerations and
translational challenges relating to cell therapy development,
manufacturing practicability, clinical trial approaches, cell quality and
persistence, and patient management remain.
antibodies
cancer therapy:
Antibodies for Cancer Therapy
Driving Breakthrough Therapies
May 4-5, 2020 Boston MA
Program
Antibodies have become the most sought-after tools in drug discovery, with
bispecific antibodies and cell engagers leading the pack of new
constructs. New insights on the tumor microenvironment and the microbiome
can determine how successful a therapeutic strategy will be, and new
imaging tools will help improve delivery of antibody drugs
https://www.pegsummit.com/Cancer-Antibodies/
ANTIBODY DRUG CONJUGATES
2020 May 6-7 BOSTON MA A
successful ADC requires the combination of the right target, right
antibody, right linker and the right payload. Getting it right can create
ADCs that have the potential to become a life-saving medicine for many
diseases, especially cancer.
https://www.pegsummit.com/Antibody-Drug-Conjugates/
Bispecific
Antibodies to the Clinic for Oncology
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Creating the Killer Combo
May 6-7, 2020 BOSTON MA
/
The development of bispecific antibodies is one of the hottest areas in biologic
research at the moment and their advancement to preclinical and clinical
development will determine what the future of this area will look like.
https://www.pegsummit.com/Bispecific-Antibodies-For-Oncology
Bispecific Antibodies for Cancer Immunotherapy
August 10-12 2020 Boston, MA
|
Engaging multiple receptors with bispecific biologics offers the potential
to improve upon single-agent checkpoint blockade and promises to be the
next generation of immunotherapy with preclinical, translational and
clinical studies on using bispecific antibodies for dual blockade of
checkpoint targets, T-cell-redirecting bispecific biologics, overcoming
T-cell exhaustion, as well as strategies to improve efficacy and reduce
toxicity, and engineer the next generation of bi- and multi-specific
biologics.
https://www.immuno-oncologysummit.com/Bispecific-Antibodies-Immunotherapy/
cancer immunotherapies:
Engineering Next-Generation
Cancer Immunotherapies
January, 2020 San Diego, CA
Based
on the clinical successes of checkpoint inhibitors, the industry is now
directing its attention to combination treatments, single agent
therapeutics with multiple modes of action, confronting resistance
mechanisms, reducing toxicity and the persistent challenge of solid
tumors.
https://www.chi-peptalk.com/cancer-immunotherapies
CAR T-cell therapy: A
type of treatment in which a patient's T cells (a type of immune system
cell) are changed in the laboratory so they will attack cancer cells. T
cells are taken from a patient’s blood. Then the gene for a special
receptor that binds to a certain protein on the patient’s cancer cells is
added in the laboratory. The special receptor is called a chimeric antigen
receptor (CAR). Large numbers of the CAR T cells are grown in the
laboratory and given to the patient by infusion. CAR T-cell therapy is
being studied in the treatment of some types of cancer. Also called
chimeric antigen receptor T-cell therapy. NCI Dictionary of Cancer Terms
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=771302
Circulating Tumor Cells
March 2-4, 2020 • San Francisco, CA
https://www.triconference.com/Circulating-Tumor-Cells | Circulating
tumor cells and cell-free tumor DNA have dominated the headlines for the
past decade and presently new liquid biopsy tests are entering the clinic.
These will enable improved diagnosis of cancer, early detection, and a new
era of companion diagnostics for therapy selection, monitoring, predicting
outcomes, and measuring the risk of recurre
Emerging Immuno-Oncology
Targets
August 11-12, 2020 Boston, MA | While
cancer immunotherapy has made a giant leap in the past five years, the
majority of therapies at advanced stages of development are clustered in a
similar target space. The increased investment in immuno-oncology has
created an urgent opportunity to discover and populate new target spaces
that either present new classes of immunotherapies or can be used in
combination with existing products.
https://www.immuno-oncologysummit.com/Immuno-Oncology-Targets/
Engineering Next-Generation Cancer Immunotherapies
January 20-21, 2020 • San Diego, CA
https://www.chi-peptalk.com/cancer-immunotherapies/ Based
on the clinical successes of checkpoint inhibitors, the industry is now
directing its attention to combination treatments, single agent
therapeutics with multiple modes of action, confronting resistance
mechanisms, reducing toxicity and the persistent challenge of solid
tumors.
immuno-oncology IO: As
our understanding of tumor immunology has advanced, immuno-oncology has made
unprecedented progress in improving the outcomes for cancer patients.
Immuno-Oncology Summit 2020 Aug 10-14
https://www.immuno-oncologysummit.com/
Immuno-Oncology Biomarkers & Companion Diagnostics
Predicting Response and Guiding Patient
Selection in IO Trials and Patient Care MARCH 2-4, 2020 San Francisco CA
Recent advances in cancer immunotherapy have
generated excitement across all fields of oncology. However, the field is
still experiencing a lack of predictive biomarkers and patient selection
remains difficult. Challenges in discovering predictive biomarkers for
cancer immunotherapy involve multiple cell types, multiple mechanisms of
T-cell regulation, genetic heterogeneity of tumors, immune components. https://www.triconference.com/Preclinical-Immuno-Oncology-Biomarkers
Immuno-Oncology
Summit Europe
March 9-12, 2020
South Quay London
https://www.immuno-oncologyeurope.com/ |
Harnessing the immune system for breakthrough therapies
Adoptive T-Cell Therapy
March
10-122, 2020 South Quay London
https://www.immuno-oncologyeurope.com/t-cell-therapy/ |
The therapeutic potential of adoptive cell therapy was first acknowledged
a couple of decades ago, but it was only recently that we transformed
adoptive cell therapy into a viable therapeutic option for patients by the
two CAR T cell therapies approved by the FDA. Although this is a very
exciting time for adoptive cell therapy, there is still much to be done to
reach its full potential including other novel cell therapies beyond T
cells.
Biomarkers for Immuno-Oncology March 11-12, 2020 South Quay
London
Patient stratification and selection is a crucial step for those
developing and providing immunotherapy. However, the heterogeneity of
tumours makes it difficult to develop accurate predictive biomarkers for
cancer patient populations. Thankfully there is a significant effort
across academia and industry to do just this. Combining outputs from
genomics, transcriptomics, proteomics and metabolomics, as well as looking
into more discreet blood niches, such as circulating tumour cells and
exosomes, may indeed provide the answers we need.
https://www.immuno-oncologyeurope.com/biomarkers-immuno-oncology
Combination Immunotherapy
March
11-12, 2020 South Quay London
|
Treating patients with an immunotherapy combination has become commonplace
for many cancers. With an abundance of combinations to choose from and
plenty more clinical trials ongoing, it is difficult to know which
combinations will be most effective. Whether double immunotherapy
combinations or immune checkpoint inhibitors combined with conventional
cancer therapy, there are numerous factors that may influence therapeutic
success, with varying degrees of supporting evidence. Predictive
biomarkers, neoantigens, therapeutic mechanism, reducing toxicity and the
immune response are all important considerations. https://www.immuno-oncologyeurope.com/combination-immunotherapy/
Immunomodulatory Approches
March
10-11 , 2020 South Quay London
| With
an abundance of immunotherapies and increasing biomarker availability,
there are ever more choices for oncologists looking to employ the immune
system in their treatment plans. The tumour microenvironment, and all its
heterogeneity, represents a huge challenge in stratifying patient
populations and selecting immunomodulatory therapies.we will discuss how
immune cells and cytokines can be activated or suppressed to elicit a
desired treatment response with a focus on T cell effectors,
myeloid-derived suppressor cells and bispecific antibody Fc engagement.
https://www.immuno-oncologyeurope.com/immunomodulatory-approache
immunotherapy:
A type of biological therapy that uses substances to stimulate or suppress
the immune system to help the body fight cancer, infection, and other
diseases. Some types of immunotherapy only target certain cells of the
immune system. Others affect the immune system in a general way. Types of
immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG),
and some monoclonal antibodies. NCI Dictionary of Cancer terms
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunotherapy
Improving
Immunotherapy Efficacy and Safety May 4-5, 2020 Boston, MA
focuses on the latest innovations, science, novel targets, and modalities
being adopted to improve immunotherapy efficacy and safety. Topics
include: new approaches to immunity, the tumor microenvironment, novel IO
targets and engineering strategies, emerging modalities, such as NK Cells
and Gamma Deltas, immune tolerance, TREGs, plus effective strategies to
mitigate toxicity. Examples will come from the world of checkpoint
inhibitors, adoptive T cell therapy, combinations, cancer vaccines,
oncolytic viruses, and novel immunotherapy approaches.
https://www.pegsummit.com/Immunotherapy
liquid biopsy:
June 15-17, 2020, Seattle WA
Biofluids
consist of circulating tumor cells (CTCs), infectious organisms, cell-free
nucleic acid (cfNA), or extracellular vesicles (EVs) from multiple tissues
or infectious agents within the body. The rapid development of highly
sensitive and accurate analytical tools allows researchers to determine
the role of these biomarkers in health, disease, and treatment response.
Thus, precision medicine is increasingly expanding into the clinic as
therapies based on these molecular profiles are actively being developed
and used in patients. Of course, before the goal of high clinical utility
can be achieved, liquid biopsies must pass rigorous analytic validation.
https://www.liquidbiopsysummit.com/
Related term: circulating tumor cells
Obtaining material for pathological examination and analysis, from bodily
fluids. Material retrieved includes CELL-FREE NUCLEIC ACIDS; CELL-DERIVED
MICROPARTICLES; EXOSOMES; CIRCULATING NEOPLASM CELLS; and other
circulating cells and CELLULAR STRUCTURES. MeSH Year introduced: 2018
Liquid biopsy enabling
technologies
August 25-26, 2020 Washington, DC
https://www.nextgenerationdx.com/circulating-tumor-cells/ | The
technologies in the liquid biopsy field have been maturing rapidly and are
on their path to revolutionize the management of cancer patients. However,
in the increasingly crowded landscape of all the diagnostic approaches, it
can be overwhelming to identify the key technologies that are showing
promises and have potential to
be implemented in clinical practices.
Neoantigen Targeted
Therapies
August 13-14, 2020 Boston, MA | Fueled
with advances in genomic technologies, personalized oncology promises to
innovate cancer therapy and target previously undruggable space.
Developments in NGS technology enabled systematic analysis of
patient-specific mutanome and opens the door to developing personalized
cancer vaccines and other therapies targeting neoantigens. https://www.immuno-oncologysummit.com/Neoantigen-Targeted-Therapies/
Neoantigens:
A neoantigenic determinant is an epitope on
a neoantigen,
which is a newly formed antigen that
has not been previously recognized by the immune system.[1] Neoantigens
are often associated with tumor
antigens
and are found in oncogenic cells.[2] Neoantigens
and, by extension, neoantigenic determinants can be formed when a protein
undergoes further modification within a biochemical pathway such as glycosylation, phosphorylation or proteolysis.
This, by altering the structure of the protein, can produce new epitopes
that are called neoantigenic determinants as they give rise to new antigenic
determinants.
Wikipedia
https://en.wikipedia.org/wiki/Neoantigenic_determinant
oncolytic virotherapy:
August 10-11, 2020 Boston MA https://www.immuno-oncologysummit.com/Oncolytic-Virus-Immunotherapy/
The use of oncolytic viruses has expanded rapidly over the past five years
with interest in the field at an all-time high following recent scientific
breakthroughs and multi-million dollar investments from big pharma.
Preclinical and Translational Immuno-Oncology
August 11-12, 2020 Boston, MA | The
recent advancements in immunotherapies, such as immune checkpoint
modulators, bispecific antibodies, and adoptive T cell transfer, are
shifting the way cancer patients are treated. Rapid development of novel
immuno-oncology programs is creating the need for predictive preclinical
models and translational strategies to understand combination
immunotherapy, study responses and resistance to cancer immunotherapy, and
identify novel biomarkers and targets.
https://www.immuno-oncologysummit.com/Preclinical-Immuno-Oncology/
Small Molecules for Immunology and Oncology
APRIL 15-16, 2020 San Diego CA
Evidence is mounting that autoimmunity/inflammation versus cancer can be
considered two sides of the same coin. Inflammation arises when the immune
system is overactive whereas cancer is largely a result of an underactive
or subverted immune system. Hence medicinal chemists often design drugs
against the same target for these seemingly opposite diseases: developing
antagonists to inhibit autoimmunity/inflammation or agonists for the same
molecular target to activate the immune system against cancer. We hope you
can join fellow chemists at this event to share strategies, successes and
challenges in discovering and optimizing drug candidates that have the
potential to be orally bioavailable modulators of the immune system be it
for cancer or other diseases.
https://www.drugdiscoverychemistry.com/Small-Molecule-Immunology
Tumor antigen:
an antigenic substance
produced in tumor cells,
i.e., it triggers an immune
response in
the host.
Tumor antigens are useful tumor
markers in
identifying tumor cells with diagnostic
tests and
are potential candidates for use in cancer
therapy.
Wikipedia accessed 2018 August 8 https://en.wikipedia.org/wiki/Tumor_antigen
tumor
microenvironment (TME):
Targeting the Tumour Microenvironment, Nov 18-19 2019, Lisbon
Portugal
innovations for enhancing the immune anti-tumour response and
overcoming inhibitory factors. It is becoming clear that many immunosuppressive
mechanisms are at work. The checkpoint inhibitors are not living up to
expectations, and for these and other antagonists to be effective, it is
necessary to control Tregs and manipulate myeloid-derived and other suppressor
cells in the tumour microenvironment (TME). The leaders in the field are also
paying attention to the role of cytokines and the importance of Fc-engagement
for effective targeting.
https://www.pegsummiteurope.com/tumour-microenvironment
tumoroid: An aggregate of cancer cells formed in
vitro Wiktionary https://en.wiktionary.org/wiki/tumoroid#English
Cancer Resources
Therapeutic indications Conferences: http://www.healthtech.com/conferences/upcoming.aspx?s=RXXS
NCI National Cancer Institute, Dictionary of
cancer terms, about 8,800 terms. http://www.cancer.gov/dictionary/
How
to look for other unfamiliar terms
IUPAC definitions are reprinted with the permission of the International
Union of Pure and Applied Chemistry.
|